CN107281182A - A kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared - Google Patents
A kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared Download PDFInfo
- Publication number
- CN107281182A CN107281182A CN201710479997.7A CN201710479997A CN107281182A CN 107281182 A CN107281182 A CN 107281182A CN 201710479997 A CN201710479997 A CN 201710479997A CN 107281182 A CN107281182 A CN 107281182A
- Authority
- CN
- China
- Prior art keywords
- cucoline
- dermatitis
- tslp
- photosensitive
- photosensitive dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared.Medicine of the present invention has obvious therapeutic action to photosensitive dermatitis；It is closely related that medicine of the present invention reduces TSLP DCs inducer T lymphocyte toxic damages to the therapeutic action of photosensitive dermatitis with it.
Description
Technical field
The invention belongs to Field of Drug Discovery, specifically, it is related to a kind of cucoline and is preparing treatment photosensitive dermatitis medicine
Application in thing.
Background technology
Photosensitive dermatitis (photoallergic dermatitis) is relatively common disease of skin, by the purple in sunlight
Outside line irradiation causes or aggravated.There is photosensitization history more photosensitive dermatitis patient, fall ill within 1-2 days generally after Exposure to Sunlight, performance
The small papule in side, vesicle are stretched for facial, neck and throat " V-arrangement area " and upper limbs and feels that sufferings are hard to bear, and severe patient can be in eczema
Sample changes.Photosensitive dermatitis can be divided into contact photosensitive dermatitis and systemic photosensitive dermatitis according to the scope of lesion, such as not
Can timely and effectively treat can develop into chronic light sensitive dermatoses.Systemic photosensitive dermatitis is on the basis of contact dermatitis
On, again occur systemic " exposing again " and produce inflammation symptom, be directed not only to scytitis, can also with headache,
The constitutional symptoms such as arthralgia, diarrhoea and vomiting, and vascular inflammation sample can be caused to damage, such case is although rare, but can give
Patient causes serious consequence, it is necessary to attach great importance to.Photosensitive dermatitis not only can bring height with prolonged and repeated breaking-out to patient
High medical expense, and have a strong impact on their quality of life.The essence of photosensitive dermatitis is the reaction of light abnormalism.In recent years
Come, photosensitive dermatitis is all in rising trend in the whole world incidence of disease, and research shows, the incidence of disease and the height above sea level of photosensitive dermatitis are in just
Correlation, negatively correlated with latitude, Yunnan Province is located in the Yunnan-Guizhou Plateau, height above sea level and latitude is low, and the ultraviolet in sunlight is strong, and it is fallen ill
Rate is higher than domestic other areas, and the Shangri-la area incidence of disease is apparently higher than areas such as Yuanjiang River, Kunming in Yunnan Province.
The reaction of light abnormalism is the process of a plyability, be related in inherent immunity and acquired immunity various kinds of cell and
Intermolecular interaction.Photoallergen (photosensitizer) is the initiation factor for causing photosensitive dermatitis, and it absorbs purple
Form photosensitizer material or photosensitizer product after the energy of outer light (UVA or UVB), and with macromolecular substances (such as protein)
Haptens-protein conjugate is combined to form, as complete antigen or new photoallergen (photoallergen), they are opened
Dynamic immune system injured skin is the main mechanism to form photosensitive dermatitis.The light of photosensitive dermatitis can be caused in daily life
Allergen species is various, and many food and chemical substance are all likely to become photoallergen.By geographical position (sunshine), habits and customs
With the influence of the factor such as work production, the species and number of various regions photoallergen be incomplete same.With social development and technology
Progressive, new compound is continuously emerged in the life of people, the species of photoallergen is also constantly changed, these chemical combination
Thing also considerably increases the risk of photosensitive dermatitis while facilitating and enriching people's life.
Photosensitive dermatitis forms the infringement to skin, thymic stromal lymphopoietin (thy mic stromal
Lymphopoietin, TSLP) activate BMDC (dendritic cells, DCs) and induce generation cytotoxic T cell
The damage of (cytotoxic T-lymphocyte, Tcl) to skin is the important mechanisms that allergic dermatitis occurs, meanwhile, we
It has also been found that after photosensitive dermatitis formed, TSLP genes and protein expression substantially increase in the research of early stage.TSLP is one kind four
The cell factor of bundle structure, has document report TSLP to belong to IL-2 cytokine family I type cytokines, also it has been reported that
It is a kind of new IL-7 like cell factors, epithelial cell and chest of the wide expression in lung, skin and internal organ during inflammatory reaction
Gland medullary substance, mucosal lymph node and tonsillotome etc. are organized, and there is overexpression in the keratinocyte of allergic dermatitis.Light sensitivity
When dermatitis occurs, photoallergen stimulates skin epithelial cell, fibroblast and mast cell etc. to produce TSLP.Research discovery,
Mouse TSLP can stimulate early stage bone-marrow-derived lymphocyte and T lymphopoiesis and differentiation, but the TSLP of people can only stimulate CD11c+
DCs, it is impossible to activate other antigen presenting cells, T lymphocytes, bone-marrow-derived lymphocyte and NKT (natural killer, NK)
Cell etc. plays immunological role, because the CD11c of the mankind+DCs IL-7 receptor alphas (IL-7R α) and TSLP acceptors
(TSLPR) mRNA has a coexpression chain, and other types of cell does not have.TSLP can be with CD11c+TSLPR on DCs and
IL-7R α are combined, but big more than TSLP-IL-7R α by the affinity and stability of TSLP-TSLPr compounds, therefore usual
In the case of, TSLP mainly activates CD11c by TSLPR+DCs.The TSLP-DCs expression II type ajor histocompatibilities being activated
Compound (main histocompatibility complex, MHC-II) and I type MHCs (main
Histocomp atibility complex, MHC-I), and CD4 can be activated simultaneously+And CD8+The anaphylaxis of helper cell mediation
Inflammation.CD8+Effect of the T lymphocytes in the morbidity and deterioration of anaphylactia is since being found that specific antigenicity CD8+T drenches
Great attention has been obtained after bar cell.TSLP-DCs can make DCs generate CD40L inductions CD8+The formation of T lymphocytes has
The responsiveness cytotoxic T lymphocyte (cytotoxic T-lymphocyte, Tcl) of obvious cytotoxicity, and secrete height
The lymphocyte of the gamma interferon (interferon- γ, INF- γ) of concentration, IL-5 and IL-13.IL-5 and IL-13 are in body
Find to induce Eosinophilia and produce IgE antibody in outer experiment to play immunology effect.TSLP-DCs passes through
MHC-II activates CD4+T helper lymphocytes produce the cytotoxicity that substantial amounts of INF- γ further strengthen Tcl (see Fig. 1).
TSLP-DCs can also stimulate CD8+T lymphocytes produce 2 cytokines (type 2cytokine), and it is anti-in allergic inflammation
It is the change-over switch of acute and chronic two kinds of immunologic mjuries in answering, during acute traumatic inflammation damnification, it promotes INF- γ rises；
And Tcl quantity is increased and cytotoxicity enhancing in chronic injury.But in allergic dermatitis, 2 cytokines were both
INF- γ concentration, which can be raised, can also increase Tcl quantity and its cytotoxicity, form the vicious circle of immunologic mjury and be
Quick property dermatitis causes the crucial cause of disease that serious eczema sample is damaged.IL-5, the IL- occurred in the inflammatory reaction of allergic dermatitis
13 and INF- γ are in addition to cytotoxic damage is caused, moreover it is possible to amplify and maintain this immune response, cause tissue damage further
Aggravate.
Contact photosensitive dermatitis and systemic photosensitive dermatitis have bright in the order of severity of extent of disease and disease
Significant difference is different, but the difference of both morbidities and immunologic mjury mechanism is currently without systematic research data.We are in early-stage Study
Middle to find, both either there is notable difference in pathological analysis or TSLP expression quantity and expression scope, it is necessary to enter
The one clear and definite cucoline of step research in two kinds of photosensitive dermatitises by suppress TSLP-DCs induce Tcl cytotoxic effects link and
Difference on target spot, the treatment for being used for both photosensitive dermatitises for cucoline provides theoretical direction.
At present to photosensitive dermatitis because without the specific medicament treated, mainly to put prevention first.Sensitive constitution has light
Allergies and contacting may cause the crowd of photosensitization material to require to avoid exposure in sunlight as far as possible in 5 days.For light
Disease patient, it is to avoid illumination simultaneously occurs with the anti-infection of 1% gentamicin soak, and patient with severe symptoms should be locally or systemically using sugared cortical hormone
Element or histamine medicine relief of symptoms simultaneously carry out diet control.These measures are mainly symptomatic treatment, lack to light sensitivity skin
The treatment means of scorching special efficacy.Studies have reported that, Chinese herb triperygium wilfordii is by suppressing the secretion of lymphopoiesis and IL-5 to contact
Property and systemic photosensitive dermatitis there is preferable curative effect.But tripterygium wilfordii chemical analysis is complicated, with the stronger heart, liver, kidney
And reproductive system toxicity, and influence the factor of its toxicity size a lot, including medicinal part, the crude drug place of production, concocting method and
Dosage etc., very big threat is brought to drug safety.Therefore, it is necessary to excavate the new medicine that can be used for treatment photosensitive dermatitis
Thing.
Caulis sinomenii is Ranales Menispermaceae root of fangji platymiscium sinomenium acutum (Sinomenium acutum Rehd.) and hair sinomenium acutum
The rattan of plants such as (S.acutum Rehd.et Wils), removes withe leaf, dries and be made after harvesting the 6-7 months.Caulis sinomenii is in cloud
South is also known as the black root of fangji, the Yunnan root of fangji, is perennial wooden defoliation liana, distributed more widely general, is distributed mainly on Wuding County, towering
The ground such as mountain, Nan Jian, Yangbi and screen side.The plant is used as medicine, and the property of medicine is bitter, flat, pungent, Return liver, the spleen channel, and major function is wind-damp dispelling, led to
Channels and collaterals, diuresis, for rheumatic and rheumatoid arthritis, limbs pain, numbness and damage etc., its main active ingredient has
Cucoline, sinoacutine, double sinoacutines, ethyl sinoacutine etc..
A kind of isoquinoline alkaloid vegetable active monomer for extracting from caulis sinomenii of cucoline (Sinomenine) system, chemistry
Name morphinan-6-one, 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methy (9 α, 13 α, 14 α)
Molecular formula：C19H23NO4, molecular weight：329.38, chemical structural formula is shown in Fig. 2, with analgesia, anti-inflammatory, anti-arrhythmia cordis and immune suppression
The pharmacological actions such as system are widely used in clinic, and presently commercially available cucoline medicine has Sinomenine, and (square pharmacy is limited in Sichuan
Company, Chinese medicines quasi-word H H51023711) and Sinomenine enteric coatel tablets (Sichuan Kingsoft meditative mind pharmaceutical Co. Ltd, Chinese medicines quasi-word
H51023564) etc., clinically it is usually used in the autoimmune diseases such as treatment rheumatism, rheumatoid arthritis[34,35].There is research
Person made research to the toxicity of cucoline, and rat is daily by 100mg/kg (b.w.) dosage continuous gavage after 6 weeks, observation
To rat blood serum GPT, GOT, BUN and arena cell without significant change.The cucoline of low dosage is to sperm motility without obvious shadow
Ring, there is slight pathological change to liver, but after being discontinued 1 week, sinus hepaticus recovers normal, and liver cell kytoplasm enriches, only a small number of
Liver cell has Mild edema.As a result show, cucoline toxicity is smaller, with good drug safety.
In recent years show on cucoline pharmaceutical research, cucoline by act on antigen presenting cell (BMDC,
Macrophage) and multiple links such as immune effector cell, have to the immunologic function of normal mouse and rat and obvious suppress to make
With.It can reduce the expression of TLR-2, TLR-4 of BMDC albumen and mRNA in blood, by suppressing NF- κ β's
Phosphorylation, the secretion of the maturing dendritic cell and IL-12 of the transduction pathway mediation of retardance TLRs-NF- κ signal betas, anti-CD4+Th1
Excessive activation.Meanwhile, cucoline can also suppress migration and the chemotactic of BMDC, reduction chemoattractant receptor molecule CCR5,
CCR7 etc. expression, reduces CXCL9, CXCL10 secretion.In mouse experiment model, the immunosuppressive action mechanism of cucoline
It is to suppress T cell subgroup, and mainly suppresses CD4+T cell, makes CD4+/CD8+T cell ratio declines and suppresses the generation of Th1 cells
IL-2.The phagocytic function of mouse macrophage can also be substantially reduced using cucoline simultaneously, mitigates mouse immune organ, such as chest
The weight of gland and spleen；Cause cGMP/cAMP ratios in mice plasma to decline, the neutrophil leucocyte of complement activation mediation can be suppressed
Aggregation；Suppress the propagation of mouse peripheral blood T cell.
The content of the invention
In view of this, the application the invention provides a kind of cucoline in treatment photosensitive dermatitis medicine is prepared.
In order to solve the above-mentioned technical problem, the invention discloses a kind of cucoline in treatment photosensitive dermatitis medicine is prepared
Application.
Further, the formulation of the medicine is one kind in tablet, pill or oral liquid.
Compared with prior art, the present invention can be obtained including following technique effect：
1) medicine of the present invention has obvious therapeutic action to photosensitive dermatitis；
2) medicine of the present invention has lower toxic reaction relative to the medicine of other treatment photosensitive dermatitises；
3) therapeutic action of the medicine of the present invention to photosensitive dermatitis reduces TSLP-DCs inducer T lymphocytes toxicity with it and damaged
Wound is closely related.
Certainly, any product for implementing the present invention it is not absolutely required to while reaching all the above technique effect.
Brief description of the drawings
Accompanying drawing described herein is used for providing a further understanding of the present invention, constitutes the part of the present invention, this hair
Bright schematic description and description is used to explain the present invention, does not constitute inappropriate limitation of the present invention.In the accompanying drawings：
Fig. 1 is TSLP-DCs inducer T lymphocyte toxic damages in background of invention；Note：Optical strain original is by all
If TSLP and its acceptor TSLPR " Receptor recognition pattern " activation DCs, subsequent naivety Th are in MHC, costimulatory signal and such as
IL-5, IL-13, IL-2 types cell and the special cytotoxicity CD8 of the lower generation of INF- γ effects+T lymphocytes lesions
The skin of position, while secreting inflammatory cytokine aggravation damaging action；
Fig. 2 is cucoline chemical constitution of the present invention；
Fig. 3 is influence (× 100) of the cucoline of the present invention to photosensitive dermatitis mouse Pathomorphology, wherein, A is represented and connect
Property photosensitive dermatitis control group is touched, B represents contact photosensitive dermatitis treatment group, and C represents systemic photosensitive dermatitis control group,
D represents systemic photosensitive dermatitis treatment group, and E represents Normal group；
Fig. 4 is the influence (100 ×) that cucoline of the present invention is expressed photosensitive dermatitis TSLP, wherein, A represents contact light
Quick property dermatitis control group, B represents contact photosensitive dermatitis treatment group, and C represents systemic photosensitive dermatitis control group, and D is represented
Systemic photosensitive dermatitis treatment group, E represents Normal group；
Fig. 5 is the integrality that inventive gel electrophoresis detection RNA is extracted；
Fig. 6 is reference gene GAPDH mRNA amplification curves of the present invention；
Fig. 7 is the amplification curve of each experimental group TSLP mRNA expression of the invention；
Fig. 8 is GAPDH of the present invention (left side) and TSLP (right side) amplified production solubility curve；
Fig. 9 is that Western blotting of the present invention detect each experimental group TSLP protein expressions, is respectively from left to right：It is empty
White control group, systemic photosensitive dermatitis cucoline treatment group, contact photosensitive dermatitis cucoline treatment group, systematicness is photosensitive
Property dermatitis Tripterygium Wilfordii Hook group, systemic photosensitive dermatitis Tripterygium Wilfordii Hook group and model control group.
Embodiment
Describe embodiments of the present invention in detail below in conjunction with embodiment, thereby to the present invention how application technology hand
Section can fully understand and implement according to this to solve technical problem and reach the implementation process of technology effect.
The invention discloses a kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared.
Specifically, auxiliary material is coordinated to prepare piece agent, pill, oral liquid etc. cucoline.
Illustrate the technique effect of the present invention with reference to specific experimental data：
First, the influence that cucoline treatment photosensitive dermatitis is expressed Pathomorphology and TSLP
One) experimental method：
1. animal and packet：Balb/c mouse 24,20 ± 2g of body weight, male and female half and half, random point 4 groups (contact is photosensitive
Property dermatitis control group, contact photosensitive dermatitis treatment group, systemic photosensitive dermatitis control group and systemic photosensitive dermatitis
Treatment group and Normal group), each 3 of every group of male and female.
2. replicate contact photosensitive dermatitis：3 days every mouse peritoneal injection endoxan 150mg/ before guidance model
Kg (b.w.), 1 time a day.Mouse back test block is lost hair or feathers, and embrocates the 20% 6- first diluted with acetone in test block for three days on end
Butylcoumariii simultaneously gives UVA10J/cm2With UVB 45mJ/cm2Dose irradiation, complete for the first time induce.7 after inducing for the first time
My god, apply 10% 6-Methylcoumarin is in test block and gives UVA 10J/cm2With UVB 45mJ/cm2Dose irradiation mouse it is double
Back of picking up the ears is excited.
3. dubbing system photosensitive dermatitis：In 2 days before guidance model every mouse peritoneal injection endoxan 150mg/
Kg (b.w.), 1 time a day.After mouse back depilation, each mouse peritoneal injection p-aminobenzene sulfonic acid acid amides 400mg/ is given within continuous 2 days
Kg (b.w.), then gives UVA 5J/cm2With UVB 0.1mJ/cm2Dose irradiation mouse depilation position induction sensitization.Irradiation
Terminate after irradiated region corner intracutaneous injection each 0.1ml of Freund's complete adjuvant, complete to induce for the first time.5 days after inducing for the first time,
Each mouse peritoneal injection p-aminobenzene sulfonic acid acid amides 400mg/kg (b.w.), then gives UVA 5J/cm2Irradiation mouse ears enter
Row is excited.
4. daily gavage 30mg/kg (b.w.) cucoline for the treatment of group, the 0.9%NaCl solution of control group gavage same volume,
Continuous treatment 30 days.
5. after treatment end, the swollen degree of measurement ear takes ear tissue to carry out pathological section, observation each group animal skin tissue inflammatory
The difference being infiltrated with, the observation of anti-TSLP immunohistochemical stainings, specify TSLP expression and the relation of photosensitive dermatitis and
The influence that cucoline treatment is expressed TSLP.
Two) result：
1st, influence of the cucoline to the swollen degree of photosensitive dermatitis mouse ear
Contact photosensitive dermatitis and systemic photosensitive dermatitis mouse model 24h after excitation, hence it is evident that ear swells,
The model group animal ear of 48h untreateds swells no significant change.Cucoline treatment group animal ear is swollen to spend 24h, 48h after excitation
Compared with model group animal, the swollen degree of ear, which has, substantially mitigates (P<0.05) (table 1), difference is statistically significant, but ear is swollen not
It is completely eliminated.
The cucoline of table 1 degree swollen to photosensitive dermatitis mouse ear influence (N=6)
Note：aP<0.05, compared with contact photosensitive dermatitis control group；bP<0.05, compareed with systemic photosensitive dermatitis
Group compares.
2nd, influence of the cucoline to photosensitive dermatitis mouse Pathomorphology
The Pathomorphology of photosensitive dermatitis shows as corium oedema and with substantial amounts of lymphocytic infiltration, contact skin
Scorching lymphocytic infiltration is main in dermis and epidermis and corium junctional area (Fig. 3 A), and the lymphocyte of systemic dermatitis
Infiltrating extrent is wider, and skin holostrome finds the lymphocyte (Fig. 3 C) of infiltration.Treated through cucoline, tissue edema and lymph are thin
Born of the same parents' infiltration significantly mitigates (Fig. 3 B, 3D).
3rd, influence of the cucoline to photosensitive dermatitis mouse TSLP protein expressions
Anti- TSLP immunohistochemical stainings are shown：No matter contact photosensitive dermatitis or systemic photosensitive dermatitis,
TSLP expression quantity all substantially increases.Contact light sensitivity inflammation TSLP, which is expressed, is closer to epidermis position, and systemic light sensitivity
Dermatitis TSLP is expressed in skin deeper position.Both expression quantity are all significantly reduced after being treated through cucoline, and dyeing is shallower, but
It is deeper compared with Normal group color, show that TSLP expression does not drop to normal group level (Fig. 4).
2nd, influence of the cucoline treatment photosensitive dermatitis to TSLP genes and protein level quantitative expression：
One) experimental method：Balb/c mouse 30, body weight：20 ± 2g, male and female half and half, random point 5 groups (normally according to group, connect
Touch property and systemic photosensitive dermatitis cucoline treatment group, systematicness and contact photosensitive dermatitis tripterygium wilfordii positive controls),
Each 3 of every group of male and female.By preceding method, the animal model of two class photosensitive dermatitis diseases, treatment group 30mg/kg are replicated
(b.w.) cucoline, positive controls tripterygium wilfordii dosage is 10mg/kg, is treated 30 days, takes ear tissue to carry out preceding method progress
The difference of real-time fluorescence quantitative PCR detection each group TSLP mRNA expression, Western Blotting detection TSLP protein expressions
Difference.
Two) result：
1st, the difference of each group TSLP mRNA expression
Test RNA its integrality of ordinary gel electrophoretic examinations extracted.Under uviol lamp, each point sample swimming lane of gel is shown
18S, 28S limpid in sight and the 5SrRNA bands slightly developed, illustrate that the RNA extracted is complete (see Fig. 5).
The amplification curve diagram of reference gene GAPTSLP target gene GAPDH mRNA in ear tissue is by fluorescent quantitation
PCR instrument is automatically generated.Amplification curve shows that fluorescence threshold is small, and amplification system is good, and knee of curve understands, exponential phase is obvious, and
Index slope is larger, amplification efficiency height (see Fig. 6,7).From solubility curve figure, two amplified productions dissolving peak is single, shows to expand
Increase more special, the false positive results (see Fig. 8) such as primer free dimer, single-stranded secondary structure or wrong amplified production.
The influence that cucoline is expressed each experimental group TSLP mRNA:Compared with blank control group, contact photosensitive dermatitis
And systemic photosensitive dermatitis model control group 2-ΔΔctValue is significantly raised, there is notable significant difference (Pa<0.05)；With it is above-mentioned
Two kinds of photosensitive dermatitis model control groups compare, and the TSLP mRNA of Liang Zhong photosensitive dermatitises treatment group are substantially reduced, and difference has
Notable significant difference (Pb<0.05), (2 are shown in Table).
The influence (2 that the cucoline of table 3 is expressed each experimental group TSLP mRNA-ΔΔct) (n=6)
Note：Compared with Normal group, Pa<0.01, compared with model control group, Pb<0.01。
2nd, the difference of each group TSLP protein expressions
After two kinds of photosensitive dermatitises are formed, TSLP expression is significantly raised in model control group ear tissue, with Normal group
Compare, P<0.05；30mg/kg cucoline and 10mg/kg Tripterygium Wilfordii Hook 30 days, can substantially reduce TSLP expression,
Compared with model control group, difference has notable significant difference (P<0.05) (see Fig. 9 and table 3).
Influence of the cucoline of table 4 to TSLP protein expressions in photosensitive dermatitis ear tissue (gray value is scanned, n=6)
*P ﹤ 0.05, are compared with Normal group▲P ﹤ 0.05, are compared with model control group
Test result indicates that, the generation of TSLP expression quantity and photosensitive dermatitis is closely related, after dermatitis is formed, TSLP
MRNA and protein expression substantially increase.Cucoline is to contact photosensitive dermatitis and systemic photosensitive dermatitis mouse model
The swollen reaction of ear has obvious inhibitory action, can reduce the swollen degree of ear and improve the performance of its Pathomorphology, reduce inflammatory cell infiltration,
Suppress the development of inflammation, there is obvious therapeutic action to photosensitive dermatitis.Cucoline is in treatment photosensitive dermatitis, to TSLP
MRNA and protein expression have obvious inhibitory action, point out its treating with suppressing the regulation of TSLP paths to photosensitive dermatitis
The cytotoxic damage of T lymphs activation is closely related, and definite regulation mechanism also needs further research to be illustrated to give.
Some preferred embodiments of invention have shown and described in described above, but as previously described, it should be understood that invention is not
Form disclosed herein is confined to, the exclusion to other embodiment is not to be taken as, and available for various other combinations, modification
And environment, and can be carried out in invention contemplated scope described herein by the technology or knowledge of above-mentioned teaching or association area
Change., then all should be in the appended power of invention and the change and change that those skilled in the art are carried out do not depart from the spirit and scope of invention
In the protection domain that profit is required.
Claims (2)
1. a kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared.
2. the application according to claim goes 1, it is characterised in that the formulation of the medicine is in tablet, pill or oral liquid
One kind.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710479997.7A CN107281182A (en) | 2017-06-22 | 2017-06-22 | A kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710479997.7A CN107281182A (en) | 2017-06-22 | 2017-06-22 | A kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281182A true CN107281182A (en) | 2017-10-24 |
Family
ID=60096988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710479997.7A Pending CN107281182A (en) | 2017-06-22 | 2017-06-22 | A kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281182A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1216701A (en) * | 1998-10-22 | 1999-05-19 | 湖南正清制药集团股份有限公司 | New use of sinomenine |
| CN103417540A (en) * | 2012-05-23 | 2013-12-04 | 史克勇 | Novel medicinal application of sinoacutine |
| KR101670865B1 (en) * | 2014-01-17 | 2016-10-31 | 주식회사 엘지생활건강 | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride |
-
2017
- 2017-06-22 CN CN201710479997.7A patent/CN107281182A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1216701A (en) * | 1998-10-22 | 1999-05-19 | 湖南正清制药集团股份有限公司 | New use of sinomenine |
| CN103417540A (en) * | 2012-05-23 | 2013-12-04 | 史克勇 | Novel medicinal application of sinoacutine |
| KR101670865B1 (en) * | 2014-01-17 | 2016-10-31 | 주식회사 엘지생활건강 | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride |
Non-Patent Citations (2)
| Title |
|---|
| KAXUO AOKI ET AL.: "Studies on photosensitivity caused by sulfa drugs—Part 6. Sensitization with p-hydroxylaminobenzene sulfonamide and histamine metabolism", 《THE JOURNAL OF DERMATOLOGY》 * |
| 火万琴等: "光敏性皮炎的中西医研究进展", 《西北国防医学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009252911C1 (en) | Composition comprising 1, 3 /1, 6 beta glucan for reducing weight | |
| Wang et al. | Total glucosides of paeony inhibit the inflammatory responses of mice with allergic contact dermatitis by restoring the balanced secretion of pro-/anti-inflammatory cytokines | |
| Kim et al. | Elm tree (Ulmus parvifolia) bark bioprocessed with mycelia of Shiitake (Lentinus edodes) mushrooms in liquid culture: Composition and mechanism of protection against allergic asthma in mice | |
| Marlina et al. | The effect of miana (coleus scutellariodes [L]) on vascular endothelial growth factor expression in Balb/C mice infected with mycobacterium tuberculosis | |
| Kokhaei et al. | Cimetidine effects on the immunosuppression induced by burn injury | |
| CN101067004A (en) | Moxa leaf polysaccharide and its use | |
| Joshi et al. | To investigate the therapeutic potential of immunochemotherapy with cisplatin+ 78 k D a+ MPL‐A against L eishmania donovani in BALB/c mice | |
| CN107281182A (en) | A kind of application of cucoline in treatment photosensitive dermatitis medicine is prepared | |
| CN109620831A (en) | Application of the crocetin in preparation treatment nonalcoholic steatohepatitis drug | |
| CN1180780C (en) | Picroside-II as one new medicine for preventing and treating allergic and inflammatory diseases | |
| CN1155380C (en) | Application of sophocarpidine oxide in preparing medicine to treat ulcerative colitis | |
| CN101856495A (en) | Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof | |
| CN105497167A (en) | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis | |
| CN106619870B (en) | Composition for treating digestive system tumor and preparation method thereof | |
| CN104721543A (en) | Traditional Chinese medicinal immunomodulator and preparation method thereof | |
| CN108703962A (en) | Purposes of the linalool compound in preparing antirheumatic | |
| CA2864816A1 (en) | A novel herbal formulation for the modulation of immune system of hiv infected patients and a process of preparation thereof. | |
| CN104784651B (en) | A kind of method for preparing the pharmaceutical preparation for treating gastric ulcer | |
| Maestroni | Role of Melatonin in Viral, Bacterial and Parasitic Infections | |
| KR20040087407A (en) | Immune stimulative constituents of ginseng saponins | |
| Kim et al. | Effects of Standardized Eriobotrya japonica Extract in LP-BM5 Murine Leukemia Viruses-Induced Murine Immunodeficiency Syndrome | |
| Sun et al. | Natural naphthoquinones isolated from Lithospermum erythrorhizon suppress dextran sulfate sodium-induced murine experimental colitis | |
| H Bower | Immunomodulatory Activity of Garlic | |
| CN1119163C (en) | Anticancer composite medicine | |
| Tega et al. | A newly devised formulation for self-medication enhances interferon-γ production and proliferation of splenic lymphocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171024 |
|
| RJ01 | Rejection of invention patent application after publication |